Trials / Completed
CompletedNCT02310464
Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
An Open-Label Study to Assess the Safety, Tolerability, and Efficacy of Active Immunotherapy With Dose Escalation and Cohort Expansion of OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal, or Breast Cancer Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- OBI Pharma, Inc · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical study is to assess the safety and tolerability and efficacy of active immunotherapy with dose escalation and cohort expansion of OBI-833 in advanced/metastatic gastric, lung, colorectal, or breast cancer subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OBI-833/OBI-821 |
Timeline
- Start date
- 2015-12-22
- Primary completion
- 2020-12-22
- Completion
- 2021-02-02
- First posted
- 2014-12-08
- Last updated
- 2022-10-03
- Results posted
- 2022-10-03
Locations
4 sites across 1 country: Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02310464. Inclusion in this directory is not an endorsement.